Assessing secondary prevention methods for cervical cancer: Costs and benefits in managed care

American Journal of Managed Care

Volumn 14, Issue SUPPL. 6, 2008, Pages

  MacDonald, Cheryl F ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; COOPERATION; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; MANAGED CARE; MONEY; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

FEMALE; HUMANS; MANAGED CARE PROGRAMS; MASS SCREENING; PREVENTIVE MEDICINE; UTERINE CERVICAL NEOPLASMS;

EID: 46049087166     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Cancer Society. Detailed guide: cervical cancer. http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=8. May 13, 2008.
2. National Committee for Quality Assurance. The state of health care quality 2006. http://www.ncqa.org/tabid/447/default.aspx. Accessed May 13, 2008.
3. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105-113.
4. Eggleston KS, Coker AL, Das IP, Cordray ST, Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal pap tests. J Womens Health (Larchmt). 2007;16(3):311-330.
5. Coste J, Cochand-Priollet B, de Cremoux P, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ. 2003;32(7392):733.
6. McCrory DC, Mather DB, Bastian L. Evaluation of Cervical Cytology: Evidence Report/Technology Assessment No. 5. (Prepared by Duke University under Contract No. 290-97-0014.) AHCPR Publication No. 99-E010. Rockville, MD: Agency for Health Care Policy and Research. February 1999. www.ahrq.gov/clinic/ epcindex.htm. Accessed November 25, 2002.
7. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-632.
8. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-459.
9. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597.
10. Sullivan SA, Wilkinson EJ, Grendys EJ Jr. Pap test imaging provides value to both patients and the lab. Trends Cervical Health. 2007;1. http://www.cervicalhealth.com/Jan2007/article1.html. Accessed October 2, 2007.
11. US National Institutes of Health, National Cancer Institute. Human papillomavirus vaccines: questions and answers. http://www.nci.nih.gov/ cancertopics/factsheet/risk/HPV-vaccine. Accessed May 13, 2008.
12. CytoCore, Inc. Screening and diagnosis of endometrial and cervical cancer. http://www.cytocoreinc.com/content.aspx?id=382. Accessed May 23, 2008.
13. Homicide Charges Are Recommended in Misread PapTests. NewYorkTimes. April 11, 1995.
14. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287(18):2382-2390.
15. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335(7609):28.
16. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288(14):1749-1757.
17. US Preventive Services Task Force (USPSTF). Screening for cervical cancer. Recommendations and rationale. http://www.ahrq.gov/clinic/3rduspstf/ cervcan/cervcanrr.htm. Accessed October 2, 2007.
18. Biscotti CV, Dawson AE, Dziura B, et al. Assisted primary screening using the automatedThinPrep Imaging System. Am J Clin Pathol. 2005;123(2):281-287.
19. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287(16):2120-2129.
20. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005;58(9):946-950.
21. IARC screening data. http://screening.iarc.fr/colpochap.php?lang= 1&chap=4. Accessed October 2, 2007.
22. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188(6):1383-1392.
23. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362(9399):1871-1876.
24. US National Institutes of Health, National Cancer Institute. The Pap test: questions and answers. http://www.cancer.gov/cancertopics/factsheet/ Detection/Pap-test. Accessed October 7, 2007.